3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
2
CNS
2
Sarcoma
1
NET
1
Conditions
Neuroendocrine Tumors
4
Thymoma
1
Sarcoma, Synovial
1
Recurrence
1
Pheochromocytoma
1
Paraganglioma
1
Osteosarcoma
1
Neuroblastoma
1
Mesothelioma
1
Meningioma
1
Medulloblastoma
1
Glioma
1
Glioblastoma
1
Esthesioneuroblastoma, Olfactory
1
Ependymoma
1
Carcinoid Tumor
1
Adrenal Gland Neoplasms
1
Adrenal Cortex Neoplasms
1
Interventions
lutetium Lu 177 dotatate
4
3-Iodobenzylguanidine
3
gallium Ga 68 dotatate
2
Temozolomide
2
Capecitabine
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
veliparib
1
vandetanib
1
olaparib
1
fludarabine phosphate
1
copper dotatate CU-64
1
cabozantinib
1
atezolizumab
1
Specimen Handling
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Lutetium-177
1
Lutetium
1
Iodine-131
1
Interleukin-13
1
Immunotherapy
1
Fluorodeoxyglucose F18
1
Everolimus
1
Erlotinib Hydrochloride
1
Drug Therapy
1
Cyclophosphamide
1
Cryosurgery
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pheochromocytoma
×
olaparib
×
NET
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled